Literature DB >> 29051974

Cardiac disease in familial Mediterranean fever.

Eren Erken1, Ertugrul Erken2.   

Abstract

Familial Mediterranean fever (FMF) is an autoinflammatory disease manifested by inflammatory attacks of peritonitis, pleuritis, pericarditis accompanied by fever and arthritis. Mutations of MEFV gene results in pyrin dysfunction, which causes uncontrolled interleukin-1 beta production and triggers the inflammatory attacks. Inflammation persists even during attack-free periods in one-third of the FMF patients. Findings of elevated proinflammatory cytokine patterns during remission as well as inflammatory attacks indicate the continuous subclinical disease activity and inflammation. Chronic inflammation was thought to be related to the cardiovascular risk in FMF patients. Main cardiac manifestations reported in FMF are pericarditis, idiopathic recurrent pericarditis, pericardiac tamponade, coronary heart disease and abnormal cardiovascular reactivity. Cardiac involvement in FMF may often be related to secondary AA amyloidosis. Deposition of amyloid may lead to cardiovascular morbidity and mortality in FMF patients. Associations of several vasculitic disorders such as Immunoglobulin A-associated vasculitis, polyarteritis nodosa and Behcet's disease are common in FMF. Appropriate prophylactic treatment with colchicine is recommended to prevent from cardiovascular risks. For those resistant to colchicine, IL-1 inhibitor agents can be used. Associated vasculitis should be treated with immunosuppressive agents. This review article aims to compile information about cardiac disease in FMF and refer to recent studies on the topic.

Entities:  

Keywords:  Amyloidosis; Atherosclerosis; Cardiovascular disease; Familial Mediterranean fever; Heart diseases; Inflammation; Vasculitis

Mesh:

Substances:

Year:  2017        PMID: 29051974     DOI: 10.1007/s00296-017-3853-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  76 in total

Review 1.  Amyloidosis in autoinflammatory syndromes.

Authors:  Laura Obici; Giampaolo Merlini
Journal:  Autoimmun Rev       Date:  2012-08-02       Impact factor: 9.754

2.  Is Familial Mediterranean Fever a thrombotic disease or not?

Authors:  Atalay Demirel; Tiraje Celkan; Ozgur Kasapcopur; Hulya Bilgen; Alp Ozkan; Hilmi Apak; Nil Arisoy; Inci Yildiz
Journal:  Eur J Pediatr       Date:  2007-04-14       Impact factor: 3.183

3.  Familial Mediterranean fever: risk factors, causes of death, and prognosis in the colchicine era.

Authors:  Servet Akar; Feride Yuksel; Mehmet Tunca; Ozgul Soysal; Dilek Solmaz; Vedat Gerdan; Ali Celik; Gercek Sen; Fatos Onen; Nurullah Akkoc
Journal:  Medicine (Baltimore)       Date:  2012-05       Impact factor: 1.889

4.  Prevalence of ischemic heart disease in patients with familial Mediterranean fever.

Authors:  P Langevitz; A Livneh; L Neumann; D Buskila; J Shemer; D Amolsky; M Pras
Journal:  Isr Med Assoc J       Date:  2001-01       Impact factor: 0.892

Review 5.  Vasculitis in the autoinflammatory diseases.

Authors:  Hagit Peleg; Eldad Ben-Chetrit
Journal:  Curr Opin Rheumatol       Date:  2017-01       Impact factor: 5.006

6.  Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.

Authors:  D Zemer; M Pras; E Sohar; M Modan; S Cabili; J Gafni
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

7.  Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa.

Authors:  Fatoş Yalçinkaya; Z Birsin Ozçakar; Ozgür Kasapçopur; Ayşenur Oztürk; Nejat Akar; Ayşin Bakkaloğlu; Nil Arisoy; Mesiha Ekim; Seza Ozen
Journal:  J Pediatr       Date:  2007-08-28       Impact factor: 4.406

8.  Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents.

Authors:  Gilad Twig; Avi Livneh; Asaf Vivante; Arnon Afek; Ari Shamiss; Estela Derazne; Dorit Tzur; Ilan Ben-Zvi; Amir Tirosh; Micha Barchana; Tamy Shohat; Eliezer Golan; Howard Amital
Journal:  Ann Rheum Dis       Date:  2013-03-16       Impact factor: 19.103

9.  Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schönlein purpura.

Authors:  Ruth Gershoni-Baruch; Yiftah Broza; Riva Brik
Journal:  J Pediatr       Date:  2003-11       Impact factor: 4.406

10.  Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever.

Authors:  Ismail Simsek; Salih Pay; Aysel Pekel; Ayhan Dinc; Ugur Musabak; Hakan Erdem; Ali Sengul
Journal:  Rheumatol Int       Date:  2007-01-17       Impact factor: 3.580

View more
  7 in total

Review 1.  Familial Mediterranean fever and atherosclerosis in childhood and adolescence.

Authors:  Olga Vampertzi; Kyriaki Papadopoulou-Legbelou; Areti Triantafyllou; Stella Douma; Efimia Papadopoulou-Alataki
Journal:  Rheumatol Int       Date:  2019-11-08       Impact factor: 2.631

Review 2.  Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments.

Authors:  Emanuele Bizzi; Lucia Trotta; Massimo Pancrazi; Mariangela Nivuori; Valeria Giosia; Luca Matteucci; Daniela Montori; Antonio Brucato
Journal:  Curr Cardiol Rep       Date:  2021-07-28       Impact factor: 2.931

3.  Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.

Authors:  Enrico Ammirati; Emanuele Bizzi; Giacomo Veronese; Matthieu Groh; Caroline M Van de Heyning; Jukka Lehtonen; Marc Pineton de Chambrun; Alberto Cereda; Chiara Picchi; Lucia Trotta; Javid J Moslehi; Antonio Brucato
Journal:  Front Med (Lausanne)       Date:  2022-03-07

Review 4.  The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.

Authors:  Eitan Giat; Ilan Ben-Zvi; Merav Lidar; Avi Livneh
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

5.  Can Calprotectin Show Subclinical Inflammation in Familial Mediterranean Fever Patients?

Authors:  Gökmen Asan; Mehmet Emin Derin; Halef Okan Doğan; Meliha Bayram; Mehtap Şahin; Ali Şahin
Journal:  J Korean Med Sci       Date:  2020-03-16       Impact factor: 2.153

6.  [Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].

Authors:  T Sahr; U Kiltz; C Weseloh; T Kallinich; J Braun
Journal:  Z Rheumatol       Date:  2020-09-30       Impact factor: 1.372

7.  Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis.

Authors:  Micol Romano; David Piskin; Roberta A Berard; Bradley C Jackson; Cengizhan Acikel; Juan J Carrero; Helen J Lachmann; Mahmut I Yilmaz; Erkan Demirkaya
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.